Inositec AG
Technoparkstrasse
Zurich
8005
Tel: 41-44-271-07-55
Website: http://inositec.com/
Email: info@inositec.com
About Inositec AG
Inositec AG is a biotech spin-off from ETH Zurich. The Company was founded in December 2015 to develop innovative new drugs using its proprietary technology Inositune™ to adjust the properties of inositol phosphate analogs. Initially, Inositec will focus on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection (CDI).YEAR FOUNDED:
December 2015
LEADERSHIP:
Founder and CEO: Mattias Ivarsson
CLINICAL TRIAL:
Please click here for clinical trial information.
9 articles about Inositec AG
-
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
11/22/2021
Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.
-
Switzerland-based Vifor Pharma is acquiring Spain’s Sanifit Therapeutics and another Swiss company, Inositec.
-
BioSpace Movers & Shakers, Oct. 9
10/9/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
10/7/2020
Inositec, a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced that Michael H. Davidson, MD, has been appointed to the Board of Directors.
-
Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
5/4/2020
Inositec, a pioneer in the development of life-saving small molecule drugs based on the natural compound inositol hexaphosphate, announced that the U.S. Patent and Trademark Office has issued a patent covering its platform of inositol phosphate analogs and specifically INS-3001, an inhibitor of pathological soft tissue calcification.
-
Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications
2/5/2020
Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate, announced that positive proof-of-concept data on INS-3001, a novel cardiovascular calcification inhibitor, were published in Nature Communications.
-
Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates
10/26/2018
Inositec announced today that INS-3001, a novel vascular calcification inhibitor, demonstrated the ability to significantly inhibit the calcification process in preclinical studies.
-
Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer
1/18/2018
Dr van Alphen has over 20 years of experience in clinical development and medical affairs, employed in roles of increasing responsibility.
-
Inositec AG Secures CHF1.4 Million In Seed Financing To Advance New Class Of Inositol Hexaphosphate-Based Drug Candidates
10/27/2016